Proteins change shape as they function, and these changes are essential for processes such as drug interactions and cellular activity. Researchers from the Tokyo University of Science developed an AI-based method called DeepAFM that is trained on millions of simulated images representing different protein states, accurately identifying transitions between closed and open states in a protein called SecA. This approach highlights the growing potential of AI to solve complex challenges in biology and medicine.

Intraoperative changes in visual signals can predict postoperative vision loss in patients undergoing surgery for recurrent craniopharyngiomas. The researchers report that a one-third drop in a key signal serves as an early warning, enabling timely surgical adjustments. This study is among the first to define a tailored threshold for these high-risk, technically challenging tumors, offering a practical step toward safer, more precise neurosurgical care.

An early warning system for sepsis, one of the deadliest infections for hospital patients, has been approved for use by the FDA, one of the first AI-based medical tools to get clearance.

The tool, developed by Johns Hopkins University researchers and now commercialized by Bayesian Health, detects sepsis hours faster than doctors and has reduced deaths by nearly 20%.

A team of Xiyuan Hospital researchers reveal circadian disruption (CD) as a key driver of cardiovascular disease (CVD) multi-organ comorbidities. Caused by sleep/eating irregularities and shift work, CD disturbs SCN-controlled peripheral rhythms, triggering damage via autonomic/metabolic imbalance and gut dysbiosis, with bidirectional harm between CD and end-organ damage. CD has distinct pathological effects on cardio-cerebral, cardio-hepatic and cardio-renal comorbidities. Chronotherapies and clock-targeted drugs show promise. The study advocates personalized chronomedicine and temporal-dimension integration for network-based CVD management.

The HGP2 Rare Disease Alliance of the Asia-Pacific Region (HGP2 RaDiAnce–APAC) was officially launched in Kuala Lumpur on May 10.

YBhg. Datuk Dr. Nor Fariza Binti Ngah, Deputy Director-General of Health (Research and Technical Support) at the Ministry of Health of Malaysia, and Hou Yong, General Manager of BGI Genomics, joined leading experts to discuss urgent priorities in rare disease diagnosis, genomics, and public health response.